Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in subjects with type 2 diabetes (SUSTAIN 1)

被引：0
|
作者：
Harashima, Shin-ichi [1 ]
Sorli, Christopher [2 ]
Tsoukas, George [3 ]
Unger, Jeffrey [4 ]
Karsbol, Julie Derving [5 ]
Hansen, Thomas [5 ]
Bain, Stephen [6 ]
机构：
[1] Kyoto Univ, Grad Sch Med, Kyoto, Japan
[2] Billings Clin Res Ctr, Billings, MT USA
[3] McGill Univ, Dept Med, Montreal, PQ, Canada
[4] Catalina Res Inst, Chino, CA USA
[5] Novo Nordisk AS, Soborg, Denmark
[6] Swansea Univ, Sch Med, Swansea, W Glam, Wales
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2016年 / 120卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PD-95
引用
收藏
页码：S121 / S121
页数：1
相关论文
共 50 条
  • [31] Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials
    Aroda, V. R.
    Ahmann, A.
    Cariou, B.
    Chow, F.
    Davies, M. J.
    Jodar, E.
    Mehta, R.
    Woo, V
    Lingvay, I
    [J]. DIABETES & METABOLISM, 2019, 45 (05) : 409 - 418
  • [32] Efficacy and safety of once-weekly semaglutide low dose 0.5 mg vs once-weekly dulaglutide high dose 1.5 mg in type 2 diabetes: a post hoc analysis of SUSTAIN 7
    Pratley, R. E.
    Aroda, V. R.
    Gondolf, T.
    Hansen, T.
    Lingvay, I.
    Ludemann, J.
    Skjoth, T. V.
    Viljoen, A.
    [J]. DIABETOLOGIA, 2019, 62 : S374 - S374
  • [33] Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials
    Jendle, Johan
    Birkenfeld, Andreas L.
    Polonsky, William H.
    Silver, Robert
    Uusinarkaus, Kari
    Hansen, Thomas
    Hakan-Bloch, Jonas
    Tadayon, Sayeh
    Davies, Melanie J.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (10): : 2315 - 2326
  • [34] Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
    Pratley, Richard E.
    Aroda, Vanita R.
    Catarig, Andrei-Mircea
    Lingvay, Ildiko
    Luedemann, Joerg
    Yildirim, Emre
    Viljoen, Adie
    [J]. BMJ OPEN, 2020, 10 (11):
  • [35] Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
    Seino, Yutaka
    Terauchi, Yasuo
    Osono, Takeshi
    Yabe, Daisuke
    Abe, Nobuyuki
    Nishida, Tomoyuki
    Zacho, Jeppe
    Kaneko, Shizuka
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (02): : 378 - 388
  • [36] The effects of once-weekly semaglutide on beta-cell function in subjects with type 2 diabetes
    Kapitza, Christoph
    Dahl, Kirsten
    Jacobsen, Jacob Bonde
    Axelsen, Mads Buhl
    Bergan, Eirik Quamme
    Flint, Anne
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S127 - S128
  • [37] Semaglutide once-weekly: improved efficacy with a new safety warning
    Coon, Scott A.
    Crannage, Erica F.
    Kerwin, Lara C.
    Guyton, Justinne E.
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (11) : 1061 - 1072
  • [38] Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes Protocol for a systematic review and meta-analysis
    Shi, Fang-Hong
    Li, Hao
    Cui, Min
    Zhang, Zai-Li
    Gu, Zhi-Chun
    Liu, Xiao-Yan
    [J]. MEDICINE, 2018, 97 (16)
  • [39] Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes
    Tuchscherer, Rhianna M.
    Thompson, Angela M.
    Trujillo, Jennifer M.
    [J]. ANNALS OF PHARMACOTHERAPY, 2018, 52 (12) : 1224 - 1232
  • [40] Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index
    Yabe, Daisuke
    Yamada, Yuichiro
    Kaku, Kohei
    Nishida, Tomoyuki
    Sato, Toshihiro
    Seino, Yutaka
    [J]. JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (07) : 1161 - 1174
12345